Samar Azawi

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study

Mahesh Kudrimoti, Amarintha Curtis, Samar Azawi et al. · Journal of Biotechnology · 2016 · 72 citations · Full text

Immunotoxicology, Innate Immune System, Immunology +19

American Society for Radiation Oncology (ASTRO) 2012 Workforce Study: The Radiation Oncologists' and Residents' Perspectives

Surjeet Pohar, Claire Y. Fung, Shane Hopkins et al. · International Journal of Radiation Oncology*Biology*Physics · 2013 · 38 citations

Nursing, Radiation Medicine, Medicine +8

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

Mahesh Kudrimoti, Amarinthia Curtis, Samar Azawi et al. · Biotechnology Reports · 2017 · 17 citations · Full text

A phase II trial of a differentiating agent (tRA) with cisplatin-VP 16 chemotherapy in advanced non-small cell lung cancer

Raghu Thiruvengadam, Joshua O. Atiba, Samar Azawi · Investigational New Drugs · 1996 · 10 citations

Oncology, Phase Ii Trial, Medicine +7

Treatment Outcomes of T4 Locally Advanced Head and Neck Cancers With Soft Tissue Invasion or Bone and Cartilage Invasion

Ly Do, Ajmel Puthawala, Nisar Syed et al. · American Journal of Clinical Oncology · 2009 · 10 citations